RudaCure Inc. (CEO Yongho Kim), a global pain therapeutics company, announced on the 11th that it will present its next-generation pain treatment pipeline research results at the Society for Neuroscience (SfN) Annual Meeting in San Diego, USA on the 19th.
Through this presentation, RudaCure will disclose preclinical data on its dual-target novel drug candidate that simultaneously modulates TRPV1 and MOR (Mu Opioid Receptor).
According to RudaCure, the candidate demonstrated excellent analgesic efficacy in various neuropathic pain animal models including diabetic peripheral neuropathy (DPN) and chemotherapy-induced peripheral neuropathy (CIPN). In the osteoarthritis (OA) model, it showed not only pain relief but also tissue damage inhibition and cartilage protective effects.
RudaCure emphasized that this candidate overcomes the fever side effects commonly reported with TRPV1-class drugs and the addiction/tolerance issues of MOR agonists, achieving both efficacy and safety. The company is accelerating IND-enabling studies for Phase 1 clinical trials based on these results.
CEO Yongho Kim stated, "We will present the innovative potential of our next-generation pain treatment at the world's largest neuroscience conference," adding, "We plan to actively advance global partnerships based on RCI002's differentiated mechanism of action."
